MARKET

NTRA

NTRA

Natera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.14
+0.55
+1.18%
After Hours: 47.14 0 0.00% 16:00 07/07 EDT
OPEN
47.40
PREV CLOSE
46.59
HIGH
48.70
LOW
46.39
VOLUME
735.38K
TURNOVER
--
52 WEEK HIGH
50.57
52 WEEK LOW
16.87
MARKET CAP
3.71B
P/E (TTM)
-27.4949
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NTRA stock price target is 56.20 with a high estimate of 66.00 and a low estimate of 42.00.

EPS

NTRA News

More
Natera Highlights Presentation Of 2 Distinct Studies At ESMO Meeting Jul. 1-4
Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, along with its collaborators, presented two distinct studies (one oral and one poster presentation) at the recent 2020 virtual ESMO
Benzinga · 12h ago
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 5d ago
Natera: Why COVID-19 Will Bring Out Q2 Shorts Leaving 2021 A Buy
Seeking Alpha - Article · 06/26 11:31
Natera expands lab facility in Austin
Seeking Alpha - Article · 06/22 15:53
Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas
PR Newswire · 06/22 14:03
Studies underway on Natera test in colorectal cancer
Seeking Alpha - Article · 06/18 15:06
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera MRD Testing
PR Newswire · 06/18 14:05
Natera Reports First Patient Enrolled In Both CIRCULATE-Japan, BESPOKE CRC Trials Using Signatera MRD Testing
Benzinga · 06/18 13:07

Industry

Medical Equipment, Supplies & Distribution
-0.86%
Healthcare Equipment & Supplies
-0.88%

Hot Stocks

Symbol
Price
%Change

About NTRA

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
More

Webull offers kinds of Natera Inc stock information, including NASDAQ:NTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTRA stock methods without spending real money on the virtual paper trading platform.